Bladder cancer cells on a pink background

ESMO 2025

Bladder cancer: Antibody–drug conjugates

Last updated: 28th Nov 2025

Published: 28th Nov 2025

What are the MOA, efficacy, and toxicity profiles of ADCs in bladder cancer?

The European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, saw leading bladder cancer experts discuss the latest research and opinions on bladder cancer care. Swipe through this educational symposium summary for expert-led updates on challenges in current treatment with antibody–drug conjugates (ADCs) and their evolving role in bladder cancer treatment.

View key insights from “Understanding MOA, efficacy, and toxicity of antibody drug conjugates (ADCs) in bladder cancer,” presented by experts at ESMO Congress 2025. Bernadett Szabados explains the mechanism of action (MOA) and key factors of ADC design, and Enrique Grande Pulido considers how best to manage their varying toxicities.

Developed by EPG Health for Medthority, independently of any sponsor.

Complete the form below to receive our regular round-up of the latest clinical news and medical education resources on Medthority, straight to your inbox.

* = required information

Name

Email address

Specialty

By providing your email address, you are opting in to receive our monthly newsletter.

Opt-in: By selecting this box, I consent to receiving marketing communications and information about Medthority's resources by email.

By submitting this form you agree to our Terms of Use and Privacy Policy. You can withdraw your consent at any time by clicking the ‘unsubscribe’ link found at the bottom of every email.

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event